independence blue cross glp 1 coverage Cross, a major #insurance company, joins a growing number of firms not covering GLP-1 drugs for #weightloss, blaming exorbitant costs. Doctors say the drugs that treat diabetes and obesity are Health Plans Dropping Coverage For

Elife 2014;3:e02523

NASH, Nonalcoholic steatohepatitis

Such formulation helps detoxify and whiten the skin, and minimize the signs of aging

Eylea (aflibercept) Disease area(s): Ophthalmology Manufacturer(s): Regeneron/Bayer 2024 Sales (USD): $9.55 billion Why it sold so well: Eylea registered strong sales in 2024, driven by the introduction of Eylea HD, which received FDA approval in 2023 and is an 8 mg formulation offering extended dosing intervals for retinal diseases

Patients using nasal spray may require more frequent titration or combination therapy to achieve comparable results to injection

Diabetes, Obesity & Metabolism, 25(1), 317